Abbott Laboratories’ stock narrative is shifting as analysts adjust their consensus price target, which has edged down slightly from $144.47 to $144.43. This recent update comes alongside a range of views shaped by the company’s varied business performance and strategic moves. Stay tuned to see how you can monitor these market perspectives and keep up with evolving updates on Abbott’s outlook.

Stay updated as the Fair Value for Abbott Laboratories shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

Analyst commentary on Abbott Laboratories in recent weeks has highlighted a mixture of optimism toward the company's long-term prospects and ongoing caution regarding valuation and near-term hurdles. Below is a summary of the main takeaways from current Wall Street research.

???? Bullish Takeaways

Benchmark analyst Bruce Jackson initiated coverage with a Buy rating and a $145 price target, citing Abbott's diversified business model and strong international expansion as providing a resilient foundation for sustainable growth.

Raymond James maintained an Outperform rating and raised its price target to $146 from $141, emphasizing the firm's ability to deliver organic revenue growth and accelerate in the Medical Devices sector. The firm is still expecting 7% to 8% organic revenue and double-digit bottom-line growth.

William Blair continues to rate Abbott shares as Outperform, noting that acquisition activity in the sector could result in meaningful value creation, particularly around the Exact Sciences deal.

Citi analyst Joanne Wuensch reiterated a Buy rating after a favorable legal ruling. She views the outcome as a positive precedent that may help the company navigate remaining litigation risks.

Key drivers earning analyst praise include execution in Medical Devices, robust international business momentum, and effective navigation of legal challenges.

???? Bearish Takeaways

Evercore ISI trimmed its price target to $142 from $144, reflecting slight disappointment after recent earnings as underlying metrics fell just short of expectations for some business segments.

While generally positive on the broader Medtech sector, Evercore ISI highlighted that growth outside of Medical Devices is experiencing some volatility, introducing near-term uncertainty.

Jefferies expressed a cautious stance surrounding Abbott’s pending acquisition of Exact Sciences, noting that the takeover premium may already be reflected in the stock price and downgrading Exact Sciences as a result.

Analysts have raised valuation and upside concerns, with some noting that recent gains may be pricing in much of the anticipated acquisition benefit. Further upside may depend on successful execution and additional catalysts.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Abbott Laboratories is in advanced talks to acquire medical-testing company Exact Sciences, with deal terms actively being discussed. Reports suggest an official announcement could come in the next few days.

The news of a potential acquisition has caused Exact Sciences shares to surge more than 25 percent. Abbott's stock price declined around 3 percent following the report.

Despite the momentum, Bloomberg notes that discussions around the Exact Sciences deal are still ongoing and subject to change. The agreement could be delayed or may ultimately not materialize.

Consensus Analyst Price Target: Decreased marginally from $144.47 to $144.43.

Discount Rate: Increased slightly from 7.83% to 7.83%.

Revenue Growth: The projected growth rate has risen from 7.49% to 7.62%.

Net Profit Margin: Declined from 17.99% to 17.53%.

Future P/E: The expected multiple has increased from 32.40x to 33.12x.

Narratives provide every investor with a powerful way to understand the story behind the numbers. On Simply Wall St, a Narrative connects a company’s unique business drivers, growth forecasts, and fair value into a simple, actionable story. It is an easy-to-follow tool used by millions to help decide on investment actions. It is continually updated as new news and earnings are released on the Community page.

Discover the full perspective on Abbott Laboratories by reading the original narrative: ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside. Follow along to stay up to date on:

How emerging markets and global demographic shifts could drive Abbott’s sustained growth and revenue diversification

The potential impact of innovation in high-margin medical devices, from the FreeStyle Libre to structural heart launches

Key risks, such as pricing pressures and regulatory hurdles, and how these influence the fair value versus today’s price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com